A B S T R A C T The syntheses of triglyceride and its precursors were increased when liver homogenates of ketotic diabetic rats were incubated with [U-14C]-glycero 3-phosphate and cofactors. Triolein sonicates produced a concentration-dependent inhibition of the synthesis of both diglyceride and triglyceride, whereas monoolein sonicates had no effect. Rat In studies on the site of inhibition oftriglyceride synthesis in the overall biosynthetic pathway, serum very low density lipoproteins produced a concentrationdependent inhibition of liver cytosolic phosphatidate phosphohydrolase activity. A higher I50 value was obtained with the hepatic enzyme of the diabetic rats. This higher I50 value was reversed to control by insulin treatment of the diabetic rats. These results indicated that the activity of this enzyme was less sensitive to inhibition by very low density lipoproteins in the ketotic diabetic state. The reduced sensitivity ofphosphatidate phosphohydrolase activity to triglyceride inhibition observed in the present studies could explain our previous observation ofan increased rate oftriglyceride synthesis in ketotic diabetic liver homogenates.
whereas monoolein sonicates had no effect. Rat serum very low density lipoproteins, like triolein sonicates, inhibited the synthesis of diglyceride and triglyceride. Furthermore, the intracellular form of very low density lipoproteins, namely nascent very low density lipoproteins, also inhibited the synthesis of diglyceride and triglyceride. A higher apparent I50 (concentration of inhibitor that produces 50% inhibition of activity) was observed in liver homogenates of ketotic diabetic rats for inhibition of triglyceride or diglyceride synthesis by triolein sonicates, serum very low density lipoproteins, high density lipoproteins, and nascent very low density lipoproteins. Insulin treatment of the diabetic rats reversed the 150 values to control.
In studies on the site of inhibition oftriglyceride synthesis in the overall biosynthetic pathway, serum very low density lipoproteins produced a concentrationdependent inhibition of liver cytosolic phosphatidate phosphohydrolase activity. A higher I50 value was obtained with the hepatic enzyme of the diabetic rats. This higher I50 value was reversed to control by insulin treatment of the diabetic rats. These results indicated that the activity of this enzyme was less sensitive to inhibition by very low density lipoproteins in the ketotic diabetic state. The reduced sensitivity ofphosphatidate phosphohydrolase activity to triglyceride inhibition observed in the present studies could explain our previous observation ofan increased rate oftriglyceride synthesis in ketotic diabetic liver homogenates.
INTRODUCTION
Previous studies in our laboratory characterized the severity of the diabetic state required for an accumulation of hepatic triglycerides (TG)1 in rats rendered diabetic with various amounts of streptozotocin (1) . A consistent 10-50-fold increase in hepatic TG content was observed in ketotic diabetic rats (1) . Further studies in liver homogenates of ketotic diabetic rats demonstrated an increased substrate flux through the TG biosynthetic pathway and increases in the activity of the key enzymes of TG synthesis (1) . An increased hepatic TG synthesis in livers of ketotic diabetic rats at a time when there was accumulation of TG suggested that the regulation of TG synthesis in these livers might have been impaired. Factors that regulate TG synthesis in liver have not been established. It is known that the synthesis of a variety of metabolites in the cell is regulated through feedback inhibition. These facts prompted us to study the potential control of hepatic TG synthesis by end product, namely, TG.
The purpose of this investigation was (a) to study the possible inhibition of TG synthesis in liver homogenates of control and diabetic rats by added triolein sonicates or a physiological form of TG, i.e., very low density lipoproteins (VLDL), (b) if an inhibition was observed, to establish the site of inhibition of TG synthesis in the TG synthetic pathway, and (c) to study the effect of insulin treatment of the ketotic diabetic rats on the kinetics of inhibition of TG synthesis.
METHODS
The sources of rats, chemicals, insulin, and methods for the induction of ketotic diabetes, insulin treatment of the diabetic rats, and assay for TG synthesis from [U-'4C]glycero-3-phosphate in liver homogenates were as described (1, 2 was dissolved in a minimal volume of chloroform; 50 mM Tris-HCl buffer, pH 7.4, containing 1.5 mg purified albumin/ ml of buffer (1), was added and the suspension was sonicated at 2°C for 30 s (Biosonik IV, Bronwill Instruments, Rochester, N. Y.). N2 gas was passed through the suspension at 37°C until it was free of chloroform. The sonicates were used within 30 min of preparation.
Preparation of serum VLDL. 36-h fasted male rats (280-320 g body wt) were decapitated and their blood was collected. The serum was separated and EDTA, pH 7.4, (1 mg/ml of serum) was added. The serum was centrifuged (model L350 ultracentrifuge, Beckman Instruments, Spinco Div., Fullerton, Calif.) at 100,000 g for 1 h and any chylomicrons present were removed by tube slicing. The density of the infranatant fluid was adjusted to 1.006 with KBr and VLDL was isolated by ultracentrifugation as described by Havel et al. (3) . The VLDL preparation was floated through saline (1.006 d) and dialyzed under N2 pressure at 4°C as described by Murthy et al. (4) . Further concentration was achieved by centrifuging on Centriflo membranes (Amicon Corp., Lexington, Mass.).
Preparation of doubly labeled serum VLDL. 36-h fasted male rats (280-320 g) were each injected intravenously with 0.2 ml of rat serum containing 1 ,umol potassium palmitate-l-14C (20 ,uCi) and 0.005 ,tmol [2-3H] glycerol (30 , uCi) . After 30 min, the rats were decapitated, serum was collected, and VLDL was isolated, washed, and concentrated as described above. The radioactive VLDL contained -0.5 x 106 dpm 14C and 0.4 x 106 dpm 3H/,umol of VLDL-TG.
Preparation of nascent VLDL. Rat liver nascent VLDL was prepared as described by Mahley et al. (5, 6) except that purified bovine serum albumin (1 mg/ml) was present during the sonication ofthe suspension ofthe golgi apparatus. The inclusion of albumin greatly reduced the aggregation of the released nascent VLDL.
Preparation of rat serum high density lipoprotein (HDL). Rat serum HDL (HDL2 + HDL3) was isolated at density 1.075 < d < 1.21 (7) . HDL was washed with saline d 1.21, dialyzed and concentrated as described for serum VLDL. The VLDL preparations exhibited a single band with pre-beta mobility and HDL a single band with alpha mobility on agarose gel electrophoresis (8) . Data obtained in incubation studies were analyzed (9) and plotted by a Hewlett-Packard Computer (model 9821 A, Hewlett-Packard Co., Palo Alto, Calif.) equipped with a plotter. I50 is defined as the concentration of inhibitor that produces 50% inhibition of activity.
Assay for cytosolic phosphatidate phosphohydrolase activity. Activity of this enzyme in liver cytosolic fraction was assayed using membrane-bound phosphatidate as described (1) . In agreement with a recent report by Lamb et al. (10) , the substitution of CaCl2 for NaF in incubation mixtures for the preparation of membrane-bound phosphatidate, resulted in an increased labeling of phosphatidate fraction and reduced counts in diglyceride (DG) fraction. Hence this procedure was adopted. Membrane-bound phosphatidate was prepared as follows: Normal rat liver microsomes were washed with 0.25 M sucrose, pH 7.4, and suspended in fresh sucrose solution. The incubation mixture contained 100 mM Tris-HCl buffer, pH 7.4; 70, M CoA; 5 mM ATP; 1.6 mM Ca21 (as chloride); 6 mM DL-[U-_4C]glycero-3-phosphate (15 ,uCi); 0.57 mM palmitate bound to purified bovine serum albumin (1) and liver microsomes (about 5 mg protein) in a total volume of 3.5 ml. After incubation for 1 h at 37°C, the microsomes were sedimented, washed, suspended in fresh sucrose solution, and heated for 2 min at 100°C to destroy microsomal endogenous phosphatidate phosphohydrolase activity (1, 11) . The specific activity of the membrane-bound phosphatidate was about 3,960 dpm/nmol.
RESULTS
A major pathway for hepatic TG synthesis is shown in Fig. 1 . In the first series of experiments, triolein sonicates were added to incubation mixtures to study their effect on the synthesis ofTG and its precursors. The addition of triolein in micromolar concentrations produced a concentration-dependent inhibition ofTG synthesis in liver homogenates of both control and ketotic diabetic rats (Fig. 2) . The concentration of triolein that was required to produce half-maximal inhibition was increased in the ketotic diabetic state (Fig. 2) . Similar results were obtained in studies on DG synthesis. Triolein had no effect on phosphatidate synthesis by liver homogenates of either control or ketotic diabetic rats. The concentration of triolein required to produce half-maximal inhibition of DG synthesis was higher than that required to produce similar inhibition of TG synthesis (Fig. 2 ). The addition of sonicates, similarly prepared but without triolein, had no inhibitory effect on either DG or TG synthesis, indicating that the triolein component ofthe sonicates was responsible for the inhibition. To check the specificity of the inhibitory lipid, these experiments were repeated using monoolein sonicates in place of triolein. Monoolein is structurally related to triolein but is not an intermediate or end product in the hepatic TG biosynthetic pathway (12) . Sonicates of monoolein had no inhibitory effect on synthesis of phosphatidate (PA), DG, or TG (Fig. 3) .
Since triolein sonicates were unphysiological suspensions, subsequent inhibition studies were done with rat serum VLDL, a physiological form of TG. Serum VLDL, when added in millimolar quantities (VLDL-TG), produced a concentration-dependent inhibition of TG synthesis by liver homogenates of both control and ketotic diabetic rats (Fig. 4 ). As observed with triolein sonicates, the concentration of VLDL-TG required to produce half-maximal inhibition was increased in liver homogenates of ketotic diabetic rats. When the diabetic rats were treated with insulin, which resulted in the reversal to control of various parameters of the diabetic state including plasma glucose, free fatty acids, /3-hydroxybutyrate and TG (1), the halfmaximal value for inhibition of TG synthesis reverted to control (Fig. 4) . DG synthesis was also inhibited by added serum VLDL (Fig. 4) . The concentration of VLDL-TG required to produce half-maximal inhibition was increased in the ketotic diabetic state, an effect reversed by insulin treatment of diabetic rats. PA synthesis was unaffected by added VLDL (Fig. 4) .
Lipoprotein Inhibition of Hepatic Triglyceride Synthesis c..QL.... Radioactivity in FFA and TG fractions (2) and the ratio of 3H/14C were determined. The results demonstrated that the radioactive VLDL was not degraded by liver homogenates of control, diabetic, and insulin-treated rats (Fig. 5A) . A constant ratio of 3H/'4C in TG throughout the incubation period (Fig. 5B ) and an absence of measurable radioactivity in the FFA fraction (not shown) demonstrated that degradation of serum VLDL followed by its resynthesis did not occur.
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Since it can be argued that serum VLDL is not the intracellular form of the lipoprotein, the inhibition studies were repeated using rat liver nascent VLDL. Nascent VLDL, like serum VLDL, produced a concentration-dependent inhibition of TG synthesis by liver homogenates of both control and ketotic diabetic rats (Fig. 6 ). As observed with serum VLDL, the half-C maximal value for inhibition ofTG synthesis by nascent VLDL was increased in the ketotic diabetic state but reverted to control values on insulin treatment of the diabetic rats (Fig. 6 ). DG synthesis was also inhibited D by nascent VLDL. The half-maximal inhibition value was increased in the liver of ketotic diabetic rats but was reversed to control on insulin treatment of the 1.5 2.0 25 diabetic rats (Fig. 6) . PA synthesis was unaffected by the addition of nascent VLDL (Fig. 6) PA phosphohydrolase activity of the liver-soluble fractions of control, ketotic diabetic, and insulin-treated JRE 6 The concentration-dependent inhibitioni b)Y rats (Fig. 8) . (18) but not in liver (12, 19 In view of the ease of preparation and better yield, further experiments were carried out uising seruimi VLDL. The requirement of a higher concentration of serum VLDL to produce half-maximnal inhibition of DG or TG synthesis was not due to the increased degradation of added V7LDL by liver homogenates of diabetic rats; in fact, none of the liver homogenates degraded V7LDL. Since serum or nascent NVLDL inhibited the synthesis of DG and TG without affecting PA synthesis, the results suggested that the locus of inhibition was at the PA phosphohydrolase site. Hepatic PA phosphohvdrolase activity has been detected in both microsomal and cytosolic fractionis (12) . Whether there are two different enzymnes or a similar enzyme distributed in two stubcelltular fractions, or whether the dual location is an artifact due to the trauma of cell breakage, has not been established. Hepatic soluble PA phosphohydrolase activity has been reported to be a rate limiting step in in vitro TG synthesis (14) .
We have focutsed our attention on the hepatic cytosolic PA phosphohydrolase activity because (a) ouir earlier work demonstrated a marked increase in its activitv in the ketotic diabetic state and the reversal of the activity to control values on insulin treatment of the rat (1), (b) changes in the activity of this enzyme correlated with changes in the rate of TG synthesis in liver; e.g., high carbohydrate feeding (20) , diabetes (1, 21) , a stubtotal hepatectomy (22) , alcohol ingestion (10, 23) , genetic obesity (24) , and treatment with lipid-lowering agents (15, 16) and (c) Whiting et al. (21) observed that the changes in hepatic TG synthesis in diabetes correlated with changes in PA phosphohvdrolase activity of the soluble buit not the microsomal enzynme.
Using membrane-bouind PA as the suibstrate, the direct assay of PA phosphohvdrolase activity demonstrated that seruLm V'LDL inhibited the activity of this enzyme. The results also showed that the concentration of 'VLDL required to produce half-maximal inhibition was increased in the ketotic diabetic state, an effect reversed by insulini treatment of the diabetic rats. Thus VLDL effects on soluble PA phosphohvdrolase activity could offer an explanation for its effect on the overall pathway. These results pinpointed an important locus of inhibition of TG synthesis by V'LDL in the overall TG biosynthetic sequence and fuirther strengthened the importance of this enzyme in the regulation of hepatic TG synthesis. Intracellular factors that regulate TG synthesis are not established. Intracellular cyclic AMIP concentration (25) , monoglceride conicentration (26) , and Ca2" concentration (27) have been proposed to play a role. The restults of this study showed that added TG couild control TG synitlhesis in cell-free preparations of liver. Wlhether stuelh control occturs in the intact hepatocvte is vet to be established. The concentrations of serum VrLDL that inhibited the in vitro TG syinthesis were in the physiological range found in the serum of normal and diabetic rats (1, 28) . Furthermore, the intracellular form of V'LDL, hepatic nascent V'LDL, also inhibited DG and TG synthesis in liver homogenates. The enzvmes of TG synthesis are found in the microsomes (and their environment) in the hepatocyte, the same site where nascenit V'LDL is svnthesized (13) . These facts suiggest that the regulation of TG synthesis by VILDL in the cell is a reasonable possibility. It is interesting to note that Kissebah and colleagues (29) concluded that a defect in feedback regulation of hepatic VLDL synthesis might be a major defect leading to hypertriglyceridemia in -diabetic patients. The results of our study showed that there Wlas a reduced sensitivity of PA phosphohvldrolase activity to TG in the ketotic diabetic state. These results may explain our previous observation of ain increased rate of hepatic TG synthesis in the diabetic state at a time when there was an accumulation of hepatic TG (1).
